首页> 外文期刊>Journal of Clinical Immunology >Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency Patients
【24h】

Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency Patients

机译:快速推动VS泵进入皮下免疫球蛋白治疗:一次性免疫缺陷患者生活质量的随机交叉研究

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Purpose Subcutaneous immunoglobulin replacement therapy (IgRT) may be administered once a week with a pump or every other day with a syringe (rapid push). The objective of the study was to compare the impact of pump and rapid push infusions on patient’s life quality index (LQI). Methods This study was a randomized, crossover, multicenter, non-inferiority trial conducted in adults with primary immunodeficiency (PID) accustomed to weekly infusions at home by pump. Patients used pump or rapid push for 3?months each according to the randomized sequence. Main criterion was PID-LQI factor I (treatment interference). Non-inferiority ratio was set at 90%. Results Thirty patients entered the study; 28 completed the two periods. IgRT exposure was similar during each period. At the end of each period, mean LQI factor 1 was 87.0 (IC95% [80.3; 94.3]) and 77.80 (IC95% [71.5; 84.7]) for pump and rapid push, respectively. There was a slightly larger effect of rapid push on treatment interference than with pump so that the primary endpoint could not be met. No difference was found on other LQI components, satisfaction (TSQM), or quality of life (SF36v2). Eight patients declared to prefer rapid push while 19 others preferred pump. Of rapid push infusions, 67.2% led to local reactions vs 71.8% of pump infusions ( p ?=?0.11) illustrating its good tolerance. Rapid push and pump infusions achieved similar trough IgG levels with similar incidence of infections. Rapid push saved 70% of administration cost when compared to pump. Conclusions Since IgRT is a lifelong treatment in PID patients, individualization of treatment is of paramount importance. Rapid push is a new administration method in the physician’s armamentarium which is preferred by some patients and is cost-effective. ClinicalTrials.gov Identifier NCT02180763 Clinical Implications Self-administration of small volumes of immunoglobulins at home, every other day, using a syringe (rapid push) is a cost-effective alternative to administration of larger volumes by pump once a week. Capsule Summary This study compared subcutaneous infusions of immunoglobulins either weekly via a pump or every other day via a syringe (rapid push). Rapid push is preferred by some patients and is cost-effective, therefore completing a physician’s armamentarium.
机译:目的,皮下免疫球蛋白替代治疗(IGRT)可以每周用泵或每隔一天用注射器(快速推动)给药一次。该研究的目的是比较泵和快速推送输液对患者的生命质量指数(LQI)的影响。方法本研究是在具有初级免疫缺陷(PID)的成年人中进行的随机,交叉,多中心,非劣质性试验,习惯于泵的每周输注。患者使用泵或快速推动3?每一个月根据随机序列。主要标准是PID-LQI因子I(处理干扰)。非劣率比设定为90%。结果30名患者进入了这项研究; 28完成了这两个时期。每期Igrt曝光相似。在每个时期结束时,平均LQI因子1为87.0(IC95%[80.3; 94.3])和77.80(IC95%[71.5; 84.7])分别用于泵和快速推动。快速推动处理干扰的效果略有较大效果,而不是泵,因此无法满足主要终点。在其他LQI组件,满意度(TSQM)或寿命质量(SF36V2)中没有发现差异。八名患者宣称更倾向于快速推动,而19其他优先泵。快速推送输液,67.2%导致局部反应与71.8%的泵输注(p?= 0.11)说明其良好的耐受性。快速推动和泵输注达到了类似的槽IgG水平,具有类似的感染发生率。与泵相比,快速推送节省了70%的管理成本。结论由于Igrt是PID患者的终身治疗,但治疗的个体化是至关重要的。快速推动是医生的盔甲的新管理方法,这些方法是一些患者的首选,并且具有成本效益。 ClinicalTrials.gov标识符NCT02180763临床局部临床启示在家里自我管理的小体积免疫球蛋白,每隔一天,使用注射器(快速推动)是每周泵施用较大卷的成本效益替代。胶囊概要该研究通过注射器(快速推动)将免疫球蛋白的皮下注射的免疫球蛋白或每隔一天进行比较。一些患者迅速推动是优选的,并且具有成本效益,因此完成了医生的盔甲。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号